Updates on Urinary Bladder Tumors With Neuroendocrine Features

Overview

Journal Adv Anat Pathol

Specialties Anatomy & Histology
Pathology

Date 2024 Mar 25

PMID 38523484

Authors

Dilara Akbulut

Hikmat Al-Ahmadie

Affiliations

Soon will be listed here.

Abstract

The most common neuroendocrine tumor in the urinary bladder is small cell carcinoma, which can be pure or mixed with components of urothelial or other histologic subtypes. Large cell neuroendocrine carcinoma of the bladder is rare and remains ill-defined but is increasingly recognized. Well-differentiated neuroendocrine tumor and paraganglioma can arise in the bladder but are very rare in this location. Recent advances in molecular characterization allowed for better classification and may offer improved stratification of these tumors.

Citing Articles

Unusual coexistence: A case of mixed small and large cell neuroendocrine tumor in a bladder previously affected by bilharzial cystitis.

Salem M, Alherek A, Van Rooyen M, Mukendi A Clin Case Rep. 2024; 12(9):e9444.

PMID: 39286755 PMC: 11403350. DOI: 10.1002/ccr3.9444.

References

Feng M, Matoso A, Epstein G, Fong M, Park Y, Gabrielson A . Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. 2023; 85(6):523-526. DOI: 10.1016/j.eururo.2023.05.023. View

Kaushik D, Frank I, Boorjian S, Cheville J, Eisenberg M, Thapa P . Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol. 2015; 22(6):549-54. DOI: 10.1111/iju.12729. View

Powles T, Rosenberg J, Sonpavde G, Loriot Y, Duran I, Lee J . Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 384(12):1125-1135. PMC: 8450892. DOI: 10.1056/NEJMoa2035807. View

Rekhtman N . Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2021; 35(Suppl 1):36-50. PMC: 8695375. DOI: 10.1038/s41379-021-00943-2. View

Giubellino A, Lara K, Martucci V, Huynh T, Agarwal P, Pacak K . Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. Am J Surg Pathol. 2015; 39(11):1488-92. PMC: 4606469. DOI: 10.1097/PAS.0000000000000534. View

Mandelkow T, Blessin N, Lueerss E, Pott L, Simon R, Li W . Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Dis Markers. 2019; 2019:2532518. PMC: 6525886. DOI: 10.1155/2019/2532518. View

Tendler S, Kanter L, Lewensohn R, Ortiz-Villalon C, Viktorsson K, De Petris L . The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. PLoS One. 2020; 15(10):e0240973. PMC: 7590528. DOI: 10.1371/journal.pone.0240973. View

Comperat E, Amin M, Epstein J, Hansel D, Paner G, Al-Ahmadie H . The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol. 2021; 28(4):196-208. DOI: 10.1097/PAP.0000000000000309. View

Liu D, Plimack E, Hoffman-Censits J, Garraway L, Bellmunt J, Van Allen E . Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016; 2(8):1094-6. PMC: 5515075. DOI: 10.1001/jamaoncol.2016.1056. View

10.

Koshkin V, Garcia J, Reynolds J, Elson P, Magi-Galluzzi C, McKenney J . Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2018; 25(1):210-221. PMC: 6333466. DOI: 10.1158/1078-0432.CCR-18-1278. View

11.

Wang G, Yuan R, Zhou C, Guo C, Villamil C, Hayes M . Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. Am J Surg Pathol. 2021; 45(10):1399-1408. PMC: 8428850. DOI: 10.1097/PAS.0000000000001740. View

12.

Neptune E, Podowski M, Calvi C, Cho J, Garcia J, Tuder R . Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J Biol Chem. 2008; 283(30):21160-9. PMC: 2475704. DOI: 10.1074/jbc.M708692200. View

13.

Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O . Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021; 39(11):1479-1496.e18. PMC: 8628860. DOI: 10.1016/j.ccell.2021.09.008. View

14.

Cattrini C, Cerbone L, Rubagotti A, Zinoli L, Latocca M, Messina C . Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study. Clin Genitourin Cancer. 2019; 17(4):e724-e732. DOI: 10.1016/j.clgc.2019.03.010. View

15.

Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree J . DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022; 27(11):940-951. PMC: 9632312. DOI: 10.1093/oncolo/oyac161. View

16.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

17.

Baine M, Febres-Aldana C, Chang J, Jungbluth A, Sethi S, Antonescu C . POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. J Thorac Oncol. 2022; 17(9):1109-1121. PMC: 9427708. DOI: 10.1016/j.jtho.2022.06.004. View

18.

Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee J . Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020; 23(6):101201. PMC: 7286965. DOI: 10.1016/j.isci.2020.101201. View

19.

Chen Y, Epstein J . Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol. 2011; 35(3):442-6. DOI: 10.1097/PAS.0b013e318208f96a. View

20.

Kouba E, Cheng L . Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics. Endocr Pathol. 2016; 27(3):188-99. DOI: 10.1007/s12022-016-9444-5. View